FDA’s elevated meeting status signals transition from biomarker data discussions to Accelerated Approval discussions OS Therapies on track to complete clinical data submission by the end of Q1 2026 New York, New York–(Newsfile Corp. – March 9, 2026) – OS Therapies Inc. (NYSE American: OSTX) (“OS Therapies” or “the Company”), …
Read More »Fathom Announces Commencement of Winter Drill Program at the Gochager Lake Project
Calgary, Alberta–(Newsfile Corp. – March 9, 2026) – Fathom Nickel Inc. (CSE: FNI) (FSE: 6Q5) (OTCQB: FNICF) (“Fathom“, or the “Company“) is pleased to announce that the winter drill program at the Gochager Lake project commenced late in the day of March 6, 2026. Drilling is expected to continue into …
Read More »Market Minds Creative Lands on DesignRush’s The Best Digital Marketing Agencies to Hire in 2026 List
Market Minds Creative was recently recognized on DesignRush’s annual Best Digital Marketing Agencies to Hire list for its strategic approach to brand growth and data-driven campaigns. Toledo, Ohio–(Newsfile Corp. – March 9, 2026) – Leading full-service digital marketing agency Market Minds Creative recently announced its inclusion in DesignRush’s annual Top …
Read More »NorthStar Appoints Key Governance Roles to Further Strengthen Oversight
Toronto, Ontario–(Newsfile Corp. – March 9, 2026) – NorthStar Gaming Holdings Inc. (TSXV: BET) (OTCQB: NSBBF) (“NorthStar” or the “Company”) today announced key governance appointments, underscoring the Company’s continued focus on strong oversight, regulatory discipline, and sound governance practices. Audit Committee The Company announced the appointment of Neal Neilinger to …
Read More »Raising awareness to avoid blindness due to Glaucoma
LVPEI hosts Glaucoma Awareness Walk with the theme ‘Uniting for a Glaucoma-Free World’ Hyderabad, 8th March 2026: L V Prasad Eye Institute (LVPEI) has planned a series of activities across its network, to commemorate World Glaucoma Week, from March 8 -14, 2026, and create awareness on an eye disease that surreptitiously affects both adults and …
Read More »Cosmo Pharmaceuticals Achieves 104.2M Revenue and 9.5M EBITDA in 2025; Proposes 2.10 Dividend; Establishes 2026 Growth Framework
Ad hoc announcement pursuant to Art. 53 LR Full Year 2025 revenue of €104.2 million, in line with guidance, with 85% recurring revenues Recurring revenues of €88.1 million, +15% year-over-year, reflecting structural business transformation EBITDA of €9.5 million, exceeding the upper end of guidance Cash, equivalents and investments of €128.3 …
Read More »Ynvisible Appoints Global Capital Markets Leader Michael Kott to Its Board of Directors
Vancouver, British Columbia–(Newsfile Corp. – March 9, 2026) – Ynvisible Interactive Inc. (TSXV: YNV) (FSE: 1XNA) (OTCQB: YNVYF) (the “Company” or “Ynvisible”) is pleased to announce the appointment of Michael Kott as a new independent member of its Board of Directors, effective March 9, 2026. Michael Kott is the Founder & CEO …
Read More »Argo Reports Positive Preliminary Results from Graphene-Enhanced Cement Testing for Stucco Applications and 3D Construction Printing
Vancouver, British Columbia–(Newsfile Corp. – March 9, 2026) – Argo Graphene Solutions Corp. (CSE: ARGO) (OTCQB: ARLSF) (FSE: 94Y) (“Argo” or the “Company”), a company focused on the development and commercialization of graphene-enhanced products for construction and agricultural applications, reports positive preliminary results from testing involving the integration of graphene …
Read More »HEALWELL AI to Announce Fourth Quarter and Year End 2025 Financial Results on March 19, 2026
HEALWELL AI to hold a conference call and simultaneous webcast on Friday, March 20, 2026, at 8:30 am ET (5:30 am PT). Toronto, Ontario–(Newsfile Corp. – March 9, 2026) – HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) (“HEALWELL” or the “Company“), a healthcare artificial intelligence company focused on preventative care, …
Read More »Defence Therapeutics Announces Closing of Private Placement of Units for Gross Proceeds of $9,595,000
Montreal, Quebec–(Newsfile Corp. – March 9, 2026) – Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), (“Defence” or the “Company“), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the closing of a private placement (the “Private Placement“) of 17,445,455 units (the “Units“) at a price of …
Read More »
Matribhumi Samachar English